The accurac\' and precision of an intelligent dosing system (IDS) for FK506 in predicting doses to achieve target drug levels has been prospectively evaluated in transplant and autoimmune pallents. For dose individualization. the knowledge base is updated with patient·specH;c feedback including the current dose. drug le\'el. und the new larget level. The studv populatIon of 147 patients consIsted of 97 transplant pata:nts /lil'er and kidneYI and 50 patients IVlth autoimmune disorders. Patients In the transplant studv group were entered sequentiallv and followed as a cohort. Patients in the autoimmune study group were randoml~' assIgned to one of three predefined FK506 concentration Windows (low. 0.1-.3; medium. O.-l-.i Previous experience has shown that drug therapy and patient care can be improved by individualizing doses in drugs exhibiting a narrow therapeutic range. large PK variability. and a relationship between plasma drug levels and clinical pharmacodynamic (PO) responses (therapeutic and adverse).6.7
vestigation for the prevenllon and control of organ rejection and the treatment of autoimmune disorders. I Preclinical studies in anlmal models and initial clinical experience suggested that FK506 has a narrow therapeutic index. large interpatient pharmacOKinetic (PKl variability with apparent dose-dependent kinetics. and plasma level-related systemic toxicities. ~.J Results from recent randomized and nonrandomlzcd clinical trials further confirm. that similar to cyclosporine A (CyAj. careful control and monitoring of plasma (blood) drug levels of FKS06 are necessary to balance the opposing risks of over-immunosuppression such as drug-induced toxicity (e.g .. nephrotoxicity. infection. tumor) and underimmunosuppression (e.g .. graft rejection). 45 Previous experience has shown that drug therapy and patient care can be improved by individualizing doses in drugs exhibiting a narrow therapeutic range. large PK variability. and a relationship between plasma drug levels and clinical pharmacodynamic (PO) responses (therapeutic and adverse). 6.7 The optimal use of current immunosuppressive drug regimens (e.g .• CsA. Prednisone. Imuran) in the solid organ transplant patient requires the need to set therapeutic goals by individualizing polydrug therapy as a function of patient status. i.e .. level of graft function. evidence of toxicity. rejection or graft-versushost disease and the current plasma CsA drug level. 8 . 9 Therefore. an accurate and simple-to-use dosing method that would predict doses and/or desired drug levels in individual patients and at the same time account for dynamic changes in physiologic status should improve patient care by a) reducing systemic drug-related toxicities. b) increasing the time spent in an effective nontoxic therapeutic range. and c) decreasing the length of hospitalization. all of which should result in a cost-benefit advantage. In a pilot study in solid-organ transplant recipients. we described our initial clinical experience with a novel IDS developed for FK506. IO The present study was undertaken to a) further evaluate the performance of this FK506 IDS in a larger sequential cohort of patients undergoing allogeneic liver and kidney transplantation and b) compare its performance in a group of patients with autoimmune disorders who were randomly assigned to predefined FKS06 plasma concentration windows.
MATERIALS AND METHODS
The FK506 IDS used in this studv is a modified artificial intelligence program design~d to learn the doselevel relationships for FK506 from dosing history and corresponding drug concentrations. The knowledge base for the IDS originally derived. consisted of steadv-state trough FK506 plasma levels in 142 adult heart. liver and kidney allograft recipients treated as both inpatients and outpatients at the University of Pittsburgh Presbyterian Medical Center under primary FK506 immunosuppressive therapy January 1. 1990 to December 31. H190. IO To (Ibjectively assess the performance of the FKS06 iDS. a cohort studv was conducted at the University of Pittsburgh ;vledical Center. The entire study population (n = 147) consisted of a total of 50 600 Patients in the autoimmune study group were randomly assigned to one of three predefined FKS06 concentration windows (0.1-0.3. 0.4-0.7. 0.8-1.3 ng/ mL as part of a concentration controlled clinical trial. The FK506 IDS was used to guide all doses to prospectively achieve the target level specified in the protocol. Predictions of plasma drug levels were made throughout the clinical course of autoimmune patients and during the first 6 weeks of the post-transplant course of transplant patients including both intravenous and oral doses of FK506.
To be eligible for this cohort study. patients were required to have consecutive doses and corresponding plasma levels obtained after achieving steadystate. i.e .. at least 3 days of the current dose at regular intervals (e.g. every 12 hours) and at least 48 hours after administration of a new dose at regular intervals. The time to steadv-state was also consistent with the average plasma terminal half-life of approximately 8-1S hours in these patients. lllz FK506 concentration in plasma was measured bv a monoclonal antibody based ELISA assay as previouslv described. I1 . 12 The coefficient of variation ot' this assay is 1i% at 1.4 ng/mL: 14,4% at 2.9 ng/mL: and 12% at 5.7 ng/mL. The effective therapeutic range for FKS06 is estimated to be 0.5-2.0 ng/mL in transplant patients and is currently being defined in patients with autoimmune disorders.
RESULTS
The performance of the lOS was assessed using standard prediction error analysis. l ] The mean prediction error (mpe). computed from the average deviation between the observed and predicted target level. was used to describe accuracv or bias. The root mean squared prediction error (rmspe). computed as the standard deviation of the prediction error was used to describe precision. If the IDS were a perfect method. the mpe and the rmspe would be zero. The 9S% confidence interval (CI) was calculated as the mean prediction error or the root mean squared pre- between a nonlinear plane and a linear plane can be ." r- We observed excellent predictive performance across all three groups studied. The accuracy (mpe) of the lOS was determmed to be -0.013 ng; mL in the combined study group. Since the 95% Cl includes lero. the lOS is without bias. The precision (rmspe) was determmed to be 0.1499 nSI mL in the combined study groups which represents less than 10% of the span of the effective therapeutic range (0.5-2.0 ngl mLI and less than the coefficient of vanation of the FK506 assay. Thus the IDS is both accurate and repro· ducible in transplant and autoimmune patients. The performance of the lOS in autoimmune patients. a cate~ory of patients excluded from the original ARTIFICIAL INTELLIGENCE ANO PHARMACOECONOMICS knowledge base. i.e .. transplant patients. is strong ev· idence of the broad applicability of artificial intelli· gence to the field of adaptive control dosing meth· ods. ' 6-'8 The performance of the FK50610S in autoimmune patients compares favorably with previously reo ported PK guided methods such as population based nomograms and Bayesian prediction methods using feedback contro!' Because feedback methods (non· linear least-squares and Bayesian estimation) are usually more precise than population nomograms. our results were compared with feedback methods. exists in PK parameters (e.g. clearance. bioavailability), such that population or patient specific PK parameter values derh'ed from pre-transplant or posttransplant PK profiles are not reliable in accurately predicting or achieving target steady-state drug levels (Qais Mekki. personal communication). It seems unlikely .that these feedback methods can significantly improve upon the performance achieved by the IDS especially given the nonlinearity in FKS06 kinetics.
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This IDS has other important potential benefits besides improved performance for achieving target levels. Because this IDS requires no previous computer experience and is user friendly. it should help minimize the learning curve and facilitate standardization of care. This is especially true for the physician prescribing a drug like FKS06 for the first time with large PK variability and a narrow therapeutic index. Similar to the introduction of an effective new immunosuppressive drug such as CsA with concurrent therapeutic drug monitoring in renal transplantation. the addition of FKS06 to the therapeutic armamentarium coupled with this IDS should also translate into a significant cost-benefit advantage. 19 Preliminary studies at the University of Pittsburgh suggest that the cost of liver transplantation under FKS06 compared with CsA may be reduced by half or more due to shorter hospital stays (16.1 vs. 3S.9 days).zo
The IDS also offers potential benefits to the new drug development process. In the case of new drugs for disorders such as AIDS. cancer: or acute refractory organ rejection. it may not be feasible to do standard intense PK sampling earlv in drug development to estimate the PK pronle. dose proportionality and bioavailabilitv. As we have shown. the IDS combined with th-e 3D graphic method requires only single steady-state plasma samples for each dose level analyzed. PK-PD analysis using only trough levels should be informative since stead v-state FKS06 trough levels closely correlate with the area under the curve. Therefore it should be possible to extract information from observational databases to estimate the response surface of a new drug and assess its linearity or nonlinearity. This 3D graphic method should also be capable of estimating the change that occurs in the surface area of the plane when there is a drug-drug interaction.
Finallv. this IDS is user friendlv and intuitive. It has been routinely used by transplant physicians without prior computer training or experience. To run the program. the physician is simply asked to make choices from menus to answer questions about a patient's condition that are relevant to anv transplant patient receiving immunosuppressive drugs. For example. if a patient exhibits signs of drug toxic-604 • J elln Pharmlcol 1993:33:599-605 ity (nephrotoxicity) and has no evidence of rejection. then a reduction in FKS06 dosage is indicated. However. the physician must choose the new target drug level based on the current FK506 level and renal function. The only keyboard input required is to enter current FK506 doses and levels and the new target level. The IDS predicts the recommended dose based on the patient's previous dose-level historv. The IDS can also be used to predict the next FK506 level given the current dose. current level and the new FKS06 dose. In short. dosing recommendations and adjustments are tailored to the individual patient.
[n conclusion. the experience gained with this IDS in several hundred transplant patients and more recently in autoimmune patients indicate that an intelligent PC based. user friendly dosing system can efficiently optimize FKs06 therapy. It also provides a practical and cost effective method for implementing concentration controlled clinical trials. Furthermore. it is probable that patients can learn to use this program as well and become more active participants in clinical decision making in a manner analogous to patient-controlled analgesia. Through maintenance of safe and effective therapeutic drug levels which can be tailored to the individual patient. this IDS should result in even greater reductions in health care costs by reducing the likelihood of druglimiting toxicity while improving the likelihood of remaining free from rejection and therefore reducing the duration of hospitalization.!O Current studies are underway to validate this and more precisely measure its pharmacoeconomic impact.
